Global Neuromuscular Blocking Agent (NMBA) Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Neuromuscular Blocking Agent (NMBA) Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Neuromuscular Blocking Agent (NMBA) report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Neuromuscular Blocking Agent (NMBA) market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Neuromuscular Blocking Agent (NMBA) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Neuromuscular Blocking Agent (NMBA) key manufacturers include AbbVie, GlaxoSmithKline, Pfizer, Hengrui Pharmaceutical, Abbott Laboratories, Fresenius Kabi, Sandoz, Somerset Therapeutics and Guike Pharmaceutical, etc. AbbVie, GlaxoSmithKline, Pfizer are top 3 players and held % sales share in total in 2022.
Neuromuscular Blocking Agent (NMBA) can be divided into Depolarizing and Non-depolarizing, etc. Depolarizing is the mainstream product in the market, accounting for % sales share globally in 2022.
Neuromuscular Blocking Agent (NMBA) is widely used in various fields, such as Hospital, Clinic, Pharmacy and Others, etc. Hospital provides greatest supports to the Neuromuscular Blocking Agent (NMBA) industry development. In 2022, global % sales of Neuromuscular Blocking Agent (NMBA) went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neuromuscular Blocking Agent (NMBA) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
AbbVie
GlaxoSmithKline
Pfizer
Hengrui Pharmaceutical
Abbott Laboratories
Fresenius Kabi
Sandoz
Somerset Therapeutics
Guike Pharmaceutical
Shanghai Pharmaceuticals
Themis Medicare
Nanjing King-Friend
Segment by Type
Depolarizing
Non-depolarizing
Hospital
Clinic
Pharmacy
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Neuromuscular Blocking Agent (NMBA) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Neuromuscular Blocking Agent (NMBA), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Neuromuscular Blocking Agent (NMBA) industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Neuromuscular Blocking Agent (NMBA) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Neuromuscular Blocking Agent (NMBA) introduction, etc. Neuromuscular Blocking Agent (NMBA) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Neuromuscular Blocking Agent (NMBA) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
North America, Europe and Asia Pacific are the key regions for Neuromuscular Blocking Agent (NMBA) industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Neuromuscular Blocking Agent (NMBA) key manufacturers include AbbVie, GlaxoSmithKline, Pfizer, Hengrui Pharmaceutical, Abbott Laboratories, Fresenius Kabi, Sandoz, Somerset Therapeutics and Guike Pharmaceutical, etc. AbbVie, GlaxoSmithKline, Pfizer are top 3 players and held % sales share in total in 2022.
Neuromuscular Blocking Agent (NMBA) can be divided into Depolarizing and Non-depolarizing, etc. Depolarizing is the mainstream product in the market, accounting for % sales share globally in 2022.
Neuromuscular Blocking Agent (NMBA) is widely used in various fields, such as Hospital, Clinic, Pharmacy and Others, etc. Hospital provides greatest supports to the Neuromuscular Blocking Agent (NMBA) industry development. In 2022, global % sales of Neuromuscular Blocking Agent (NMBA) went into Hospital filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Neuromuscular Blocking Agent (NMBA) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
AbbVie
GlaxoSmithKline
Pfizer
Hengrui Pharmaceutical
Abbott Laboratories
Fresenius Kabi
Sandoz
Somerset Therapeutics
Guike Pharmaceutical
Shanghai Pharmaceuticals
Themis Medicare
Nanjing King-Friend
Segment by Type
Depolarizing
Non-depolarizing
Segment by Application
Hospital
Clinic
Pharmacy
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Neuromuscular Blocking Agent (NMBA) market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Neuromuscular Blocking Agent (NMBA), product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Neuromuscular Blocking Agent (NMBA) industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Neuromuscular Blocking Agent (NMBA) in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Neuromuscular Blocking Agent (NMBA) introduction, etc. Neuromuscular Blocking Agent (NMBA) Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Neuromuscular Blocking Agent (NMBA) market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices